Nuernisha Alifu

NIR-activated dual-mode oxygen-generating and -delivering nanoplatform for enhanced photodynamic therapy of cervical cancer

NIR-activated IFHFC nanoparticles enable NIR-I/NIR-II imaging and dual oxygenation (CAT-catalyzed O 2 generation and PFH O 2 release), relieving hypoxia and boosting ROS for enhanced PDT.

NIR Triggered Bionic Bilayer Membrane-Encapsulated Nanoparticles for Synergistic Photodynamic, Photothermal and Chemotherapy of Cervical Cancer

A synergistic treatment strategy of phototherapy and chemotherapy has been shown to improve efficacy and offer unique advantages over monotherapy. The purpose of this study is to explore a new nanocarrier system with liposome as the inner membrane and erythrocyte membrane as the outer membrane, which aims to realize the leak-free load of phototherapy drug indocyanine green (ICG) and chemotherapy drug doxorubicin (DOX), prolong the circulation time in vivo and improve the therapeutic effect. In this study, bilayer membrane-loaded ICG and DOX nanoparticles (RBC@ICG-DOX NPs) were prepared and characterized. For in vitro analysis, the biocompatibility and tumor inhibition properties of the nanoparticles were evaluated. For in vivo analysis, the antitumor properties of the nanoparticles were explored in a mouse subcutaneous tumor model. RBC@ICG-DOX NPs were successfully prepared with strong safety and good blood compatibility, which can effectively reduce drug leakage and prolong drug circulation time in the body. In vitro performance evaluation showed that RBC@ICG-DOX NPs obtained excellent photothermal conversion ability and well reactive oxygen generation performance under near-infrared laser irradiation. Both in vitro and in vivo experiments showed well phototherapy-chemotherapy effect of RBC@ICG-DOX NPs with low toxic side effects. Drug delivery, imaging and tumor synergies were accomplished through combinatorial strategies as well as bilayer membrane encapsulation, opening up a new platform for the design of future tumor combination therapies.

Ultrabright NIR-IIb Fluorescence Quantum Dots for Targeted Imaging-Guided Surgery

Pioneering approaches for precise tumor removal involve fluorescence-guided surgery, while challenges persist, including the low fluorescence contrast observed at tumor boundaries and the potential for excessive damage to normal tissue at the edges. Lead/cadmium sulfide quantum dots (PbS@CdS QDs), boasting high quantum yields (QYs) and vivid fluorescence, have facilitated advancements in the second near-infrared window (NIR-II, 900-1700 nm). However, during fluorescent surgical navigation operations, hydrophilic coatings of these inorganic nanoparticles (NPs) guarantee biosafety; it also comes at the expense of losing a significant portion of QY and NIR-II fluorescence, causing heightened damage to normal tissues caused by cutting edges. Herein, we present hydrophilic core-shell PbS@CdS@PEG NPs with an exceptionally small diameter (∼8 nm) and a brilliant NIR-IIb (1500-1700 nm) emission at approximately 1600 nm. The mPEG-SH (MW: 2000) addresses the hydrophobicity and enhances the biosafety of PbS@CdS QDs.

Near‐infrared emissive polymer‐coated IR ‐820 nanoparticles assisted photothermal therapy for cervical cancer cells

Abstract Photothermal therapy (PTT) has attracted wide attention due to its noninvasiveness and its thermal ablation ability. As photothermal agents are crucial factor in PTT, those with the characteristics of biocompatibility, non‐toxicity and high photothermal stability have attracted great interest. In this work, new indocyanine green (IR‐820) was utilized as a photothermal agent and near‐infrared (NIR) fluorescence imaging nanoprobe. To improve the biocompatibility, poly(styrene‐co‐maleic anhydride) (PSMA) was utilized to encapsulate the IR‐820 molecules to form novel IR‐820@PSMA nanoparticles (NPs). Then, the optical and thermal properties of IR‐820@PSMA NPs were studied in detail. The IR‐820@PSMA NPs showed excellent photothermal stability and biocompatibility. The cellular uptaking ability of the IR‐820@PSMA NPs was further confirmed in HeLa cells by the NIR fluorescent confocal microscopic imaging technique. The IR‐820@PSMA NPs assisted PTT of living HeLa cells was conducted under 793 nm laser excitation, and a high PTT efficiency of 73.3% was obtained.

A novel TMTP1-modified theranostic nanoplatform for targeted in vivo NIR-II fluorescence imaging-guided chemotherapy for cervical cancer

A novel IR-783-DOX-TMTP1 theranostic nanoplatform with strong targeting ability was prepared and used for in vivo NIR-II fluorescence imaging of intratumoral vessels and chemotherapy of cervical tumor-bearing mice.

Targetable Biomimetic NIR-II Theranostic Nanoplatform for Highly Efficient Multimodal Imaging-Guided Photothermal Therapy of Cervical Cancer

Cervical cancer (CC) is still the fourth most common cause of cancer deaths in women. However, current biomedical imaging techniques exhibit inherent limitations in the diagnosis and treatment of CC. This study aims to develop a biomimetic nanoplatform based on tumor cell membranes, loaded with a palladium (Pd)-based computed tomography (CT) contrast agent and the near-infrared (NIR) fluorescent probe indocyanine green (ICG). This multifunctional nanoplatform is designed to integrate multimodal imaging with photothermal therapy (PTT), thereby improving the diagnostic accuracy and therapeutic efficacy against CC. In this study, biomimetic nanoparticles (NPs), designated as M@Pd-ICG NPs, were synthesized by encapsulating Pd and ICG within HeLa cell membranes derived from cell-derived xenograft (CDX) models. Subsequently, the toxicity, biocompatibility, and tumor suppression capability of the M@Pd-ICG NPs were evaluated in vitro. In vivo, the multimodal imaging performance of the M@Pd-ICG NPs and their photothermal therapeutic efficacy under 808-nm laser irradiation were investigated in mouse model bearing subcutaneous cervical tumor. The M@Pd-ICG NPs were successfully prepared and exhibited favorable stability, excellent photothermal conversion efficiency (34.04%), and good biocompatibility, enabling homologous targeting and prolonged circulation time. The M@Pd-ICG NPs integrated the complementary advantages of NIR-II fluorescence imaging (900-1700 nm, NIR-II FI), photothermal imaging (PTI), and CT imaging. Both in vitro and in vivo studies demonstrated that, under 808-nm laser irradiation, M@Pd-ICG NPs induced significant photothermal effects and tumor ablation. M@Pd-ICG NPs successfully integrate multimodal imaging and PTT, owing to their excellent targeting capability and good biocompatibility, demonstrating potential for further biomedical applications.